Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LianBioLIAN · Entity 9881 | Director | June 21, 2023 | June 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LianBio
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-06-21 | Direct | 36,300 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 36,300 · Balance 36,300 F1: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2023 Filed Jun 23, 2023 20:23 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 36,300 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001831283-23-000095 · wk-form4_1687551779.xml · derivative · entry 1 Chen Wei Wei · CIK 0001919307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Underlying: Ordinary Shares · 36,300 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 20:27 UTC | LianBio LIAN · Entity 9881 | GrantStock Option (Right to Buy) · Derivative | 72,600 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0000899243-22-014353 · doc4.xml · derivative · entry 1 Chen Wei Wei · CIK 0001919307 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,600 Underlying: Ordinary Shares · 72,600 shares Expires 2032-04-06 F1 · derivative.exercise_date: 1/36 of the shares underlying the option will become exercisable on 05/06/2022; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on 04/06/2025, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.